Is Bristol Myers Squibb’s Shift Into Value-Defensive Indices Reshaping The Investment Case For BMY?
In late June 2026, Bristol-Myers Squibb was removed from several Russell growth benchmarks and added to the Russell 1000 Value-Defensive and Russell 1000 Defensive indices, marking a reclassification of the stock within major index families. This shift signals that index providers now view Bristol-Myers Squibb more as a defensive, income-oriented holding than a growth-driven pharmaceutical name, aligning with its dividend profile and efforts to manage patent expirations. Next, we will...
In late June 2026, Bristol-Myers Squibb was removed from several Russell growth benchmarks and added to the Russell 1000 Value-Defensive and Russell 1000 Defensive indices, marking a reclassification of the stock within major index families. This shift signals that index providers now view Bristol-Myers Squibb more as a defensive, income-oriented holding than a growth-driven pharmaceutical name, aligning with its dividend profile and efforts to manage patent expirations. Next, we will...
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
